131 related articles for article (PubMed ID: 38635936)
21. Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers.
Crosbie A; Le TK; Zhang Y; Das R; Ades F; Davis C; Gogate A
Future Oncol; 2023 Jan; 19(3):229-244. PubMed ID: 36974619
[TBL] [Abstract][Full Text] [Related]
22. Real-World Outcomes Among Older Mexican Women with Breast Cancer Treated with Neoadjuvant Chemotherapy.
Cabrera-Galeana P; Soto-Perez-de-Celis E; Reynoso-Noveron N; Villarreal-Garza C; Lara-Medina F; Alvarado-Miranda A; Espinosa-Fernandez JR; Esparza-Arias N; Mohar A; Bargallo-Rocha JE
Oncologist; 2020 Dec; 25(12):1023-1031. PubMed ID: 32275801
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.
Vici P; Pizzuti L; Natoli C; Moscetti L; Mentuccia L; Vaccaro A; Sergi D; Di Lauro L; Trenta P; Seminara P; Santini D; Iezzi L; Tinari N; Bertolini I; Sini V; Mottolese M; Giannarelli D; Giotta F; Maugeri-Saccà M; Barba M; Marchetti P; Michelotti A; Sperduti I; Gamucci T
Breast Cancer Res Treat; 2014 Oct; 147(3):599-607. PubMed ID: 25234842
[TBL] [Abstract][Full Text] [Related]
24. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
[TBL] [Abstract][Full Text] [Related]
25. Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation: The Breast Cancer Quality of Care (BQUAL) Study.
Greenlee H; Neugut AI; Falci L; Hillyer GC; Buono D; Mandelblatt JS; Roh JM; Ergas IJ; Kwan ML; Lee M; Tsai WY; Shi Z; Lamerato L; Kushi LH; Hershman DL
JAMA Oncol; 2016 Sep; 2(9):1170-6. PubMed ID: 27243607
[TBL] [Abstract][Full Text] [Related]
26. Taxanes for adjuvant treatment of early breast cancer.
Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
[TBL] [Abstract][Full Text] [Related]
27. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy de-escalation using an
Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
Gandhi S; Fletcher GG; Eisen A; Mates M; Freedman OC; Dent SF; Trudeau ME
Curr Oncol; 2015 Mar; 22(Suppl 1):S82-94. PubMed ID: 25848343
[TBL] [Abstract][Full Text] [Related]
30. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Earl H; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Rea D; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mahler-Araujo B; Provenzano E; Chhabra A; Gasson S; Balmer C; Abraham JE; Caldas C; Hall P; Shinkins B; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA
Health Technol Assess; 2020 Aug; 24(40):1-190. PubMed ID: 32880572
[TBL] [Abstract][Full Text] [Related]
31. Using natural language processing to improve efficiency of manual chart abstraction in research: the case of breast cancer recurrence.
Carrell DS; Halgrim S; Tran DT; Buist DS; Chubak J; Chapman WW; Savova G
Am J Epidemiol; 2014 Mar; 179(6):749-58. PubMed ID: 24488511
[TBL] [Abstract][Full Text] [Related]
32. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
33. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
34. Breast Cancer Chemoprevention in an Integrated Health Care Setting.
Nichols HB; Stürmer T; Lee VS; Anderson C; Lee JS; Roh JM; Visvanathan K; Muss H; Kushi LH
JCO Clin Cancer Inform; 2017 Nov; 1():1-12. PubMed ID: 30657366
[TBL] [Abstract][Full Text] [Related]
35. Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study.
O'Shaughnessy J; Robert N; Annavarapu S; Zhou J; Sussell J; Cheng A; Fung A
Breast Cancer Res Treat; 2021 Jun; 187(3):903-913. PubMed ID: 33649981
[TBL] [Abstract][Full Text] [Related]
36. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
[TBL] [Abstract][Full Text] [Related]
37. A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
Brown J; Scardo S; Method M; Schlauch D; Misch A; Picard S; Hamilton E; Jones S; Burris H; Spigel D
BMC Cancer; 2022 May; 22(1):502. PubMed ID: 35524219
[TBL] [Abstract][Full Text] [Related]
38. Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data.
Mandelblatt JS; Huang K; Makgoeng SB; Luta G; Song JX; Tallarico M; Roh JM; Munneke JR; Houlston CA; McGuckin ME; Cai L; Clarke Hillyer G; Hershman DL; Neugut AI; Isaacs C; Kushi L
J Oncol Pract; 2015 Jan; 11(1):e1-8. PubMed ID: 25161127
[TBL] [Abstract][Full Text] [Related]
39. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
